Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

VERA

Vera Therapeutics Inc

Mar 12 • 04:00PM ET

28.18

Dollar change -0.18
Percentage change -0.63	%

Healthcare • Biotechnology • USA • NASD

Peers: ARVN INCY ITCI ALXO BCRX RIGL LGND KURA CRVS AVIR

| Held by: VTI IWM VXF XBI IWO IBB SCHA VTWO VHT LABU

Index	RUT	P/E	-	EPS (ttm)	-2.74	Insider Own	23.27%	Shs Outstand	63.56M	Perf Week	-5.94%
Market Cap	1.80B	Forward P/E	-	EPS next Y	-3.15	Insider Trans	-1.51%	Shs Float	48.92M	Perf Month	-21.46%
Income	-152.15M	PEG	-	EPS next Q	-0.73	Inst Own	91.42%	Short Float	15.94%	Perf Quarter	-41.85%
Sales	0.00M	P/S	-	EPS this Y	-14.38%	Inst Trans	21.66%	Short Ratio	9.31	Perf Half Y	-26.40%
Book/sh	9.08	P/B	3.10	EPS next Y	-0.30%	ROA	-36.61%	Short Interest	7.80M	Perf Year	-36.39%
Cash/sh	10.05	P/C	2.80	EPS next 5Y	7.46%	ROE	-44.83%	52W Range	25.99 - 51.61	Perf YTD	-33.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	4.49%	ROI	-24.14%	52W High	-45.40%	Beta	1.18
Dividend TTM	-	Quick Ratio	25.58	Sales past 5Y	0.00%	Gross Margin	-	52W Low	8.43%	ATR (14)	1.94
Dividend Ex-Date	-	Current Ratio	25.58	EPS Y/Y TTM	-20.03%	Oper. Margin	-	RSI (14)	38.54	Volatility	5.73% 7.40%
Employees	112	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.15	Target Price	65.00
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-24.62%	Payout	-	Rel Volume	0.57	Prev Close	28.36
Sales Surprise	-	EPS Surprise	11.35%	Sales Q/Q	-	Earnings	Feb 26 BMO	Avg Volume	837.47K	Price	28.18
SMA20	-3.48%	SMA50	-17.26%	SMA200	-27.43%	Trades		Volume	476,914	Change	-0.63%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-04-25	Initiated	Wolfe Research	Outperform	$49
Jan-28-25	Initiated	Goldman	Buy	$58
Nov-21-24	Initiated	Wells Fargo	Overweight	$70
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jan-25-24	Initiated	Oppenheimer	Outperform	$26
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform	$29
Nov-10-23	Upgrade	Jefferies	Hold → Buy	$18 → $26
Aug-16-23	Initiated	Guggenheim	Buy	$27
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral	$33 → $8
Jan-04-23	Downgrade	Jefferies	Buy → Hold	$32 → $6
Jul-12-22	Initiated	JP Morgan	Overweight	$35
May-02-22	Initiated	H.C. Wainwright	Buy	$35
Apr-19-22	Initiated	Wedbush	Outperform	$32

Show Previous Ratings

Mar-11-25 04:28PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 08:00AM	Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) +5.91%
Feb-26-25 08:25AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-13-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -19.66%
Jan-14-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Loading…
Jan-13-25 07:00AM	Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor (GlobeNewswire) -6.08%
Jan-07-25 04:05PM	Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 06:29PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-22-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-18-24 08:00AM	Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer (GlobeNewswire)
Nov-11-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:55AM	Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet (Zacks)
08:00AM	Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study (GlobeNewswire)
Nov-08-24 04:05PM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 08:00AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
08:21PM	Loading…
Oct-29-24 08:21PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire) -9.23% -5.42%
09:25AM	Vera Therapeutics price target raised to $64 from $56 at Guggenheim (TipRanks)
Oct-28-24 05:43PM	Vera Therapeutics Breaks Out On Promising Results For Kidney Drug (Investor's Business Daily) +15.21%
05:37PM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
10:33AM	Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years (Benzinga)
10:13AM	Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug (Investor's Business Daily)
Oct-26-24 07:30PM	Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
Oct-04-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-24 06:30AM	Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
06:30AM	Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases (GlobeNewswire)
Sep-26-24 03:31PM	Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024? (Insider Monkey)
Sep-16-24 08:00AM	Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024 (GlobeNewswire) +6.90%
Sep-12-24 08:00AM	Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN (GlobeNewswire) -5.08%
Sep-10-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
08:27AM	Loading…
Sep-03-24 08:27AM	Adobe Stock Added to JP Morgan Focus List. Heres Why. (Barrons.com)
08:27AM	Adobe and 2 More Stocks Added to JP Morgan Focus List. Heres Why. (Barrons.com)
07:49AM	Load Up on Adobe and These 2 Stocks This September, J.P. Morgan Says (Barrons.com)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 08:00AM	Vera Therapeutics to Participate at September Investor Conferences (GlobeNewswire)
Aug-09-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 08:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-05-24 04:30PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-24 08:00AM	Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer (GlobeNewswire)
Jun-11-24 04:01PM	Vera Therapeutics Appoints Christy J. Oliger to Board of Directors (GlobeNewswire)
Jun-07-24 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-24 08:00AM	Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN) (GlobeNewswire)
May-25-24 09:40AM	Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress (GlobeNewswire)
May-17-24 04:27PM	Vera Therapeutics Insider Sold Shares Worth $1,304,435, According to a Recent SEC Filing (MT Newswires)
May-10-24 05:38AM	Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating (MT Newswires)
May-09-24 01:53PM	VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024 (InvestorPlace) -5.81%
08:00AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 04:38PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-23-24 05:09PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Apr-13-24 05:29AM	Could This Stock Be the Next Biotech Buyout? (Motley Fool)
Apr-12-24 07:01PM	Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ... (GuruFocus.com)
Apr-11-24 04:29PM	Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal (Yahoo Finance Video) +17.30%
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-02-24 08:00AM	Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress (GlobeNewswire)
Mar-20-24 12:52PM	VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:30AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-28-24 04:20PM	Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-02-24 12:40PM	Hedge Fund and Insider Trading News: Anthony Scaramucci, Ray Dalio, Ken Griffin, NWQ Capital Management, Man Group, Cleveland-Cliffs Inc (CLF), Vera Therapeutics, Inc. (VERA), and More (Insider Monkey)
08:00AM	Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Feb-01-24 04:05PM	Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Class A Common Stock (GlobeNewswire)
Jan-29-24 11:50PM	Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock (GlobeNewswire) +11.46%
06:15AM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
Jan-25-24 06:30AM	Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy (GlobeNewswire) +48.71%
Jan-12-24 06:44PM	Why Vera Therapeutics Stock Soared by 22% This Week (Motley Fool) -11.35%
Jan-08-24 08:01AM	Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer (GlobeNewswire) +16.74%
08:00AM	Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024 (GlobeNewswire)
Dec-27-23 08:00AM	Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-23 10:15AM	This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street (Motley Fool) +8.70%
Nov-14-23 05:05PM	FMR LLC Adjusts Stake in Vera Therapeutics Inc (GuruFocus.com) +6.74%
09:55AM	Wall Street Analysts Believe Vera Therapeutics, Inc. (VERA) Could Rally 86.76%: Here's is How to Trade (Zacks)
Nov-09-23 09:29AM	Vera Therapeutics Inc (VERA) Reports Q3 Financial Results and Business Updates (GuruFocus.com)
08:00AM	Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results (GlobeNewswire)
Nov-04-23 10:00AM	Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023 (GlobeNewswire)
Oct-30-23 08:00AM	Vera Therapeutics Scheduled to Present at November Investor Conferences (GlobeNewswire) +8.32%
Oct-18-23 09:35AM	Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA) (Zacks) -5.09%
Oct-17-23 09:35AM	Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA) (Zacks)
Oct-16-23 09:35AM	Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround (Zacks)
Oct-13-23 10:22AM	Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting (GlobeNewswire)
Sep-26-23 04:02PM	Why Shares of Vera Therapeutics Jumped Tuesday (Motley Fool) +11.32%
Aug-31-23 08:00AM	Vera Therapeutics Scheduled to Present at September Investor Conferences (GlobeNewswire) -5.70%
Aug-16-23 10:00AM	Chevron upgraded, SolarEdge downgraded: Wall Street's top analyst calls (The Fly)
Aug-15-23 04:03PM	What Makes Vera Therapeutics, Inc. (VERA) a New Buy Stock (Zacks)
Aug-10-23 08:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results (GlobeNewswire) +6.22%
Aug-04-23 06:30PM	Apogee Therapeutics, Turnstone Biologics, and More Stocks See Action From Activist Investors (Barrons.com)
Jul-24-23 09:01AM	Positive Signs As Multiple Insiders Buy Vera Therapeutics Stock (Simply Wall St.) -6.82%
Jul-07-23 06:35PM	Masimo and Vera Therapeutics Stock See Action From Activist Investors (Barrons.com) +5.20%
Jun-27-23 08:05AM	Vera Therapeutics Likely Needs Time to Digest Its Recent Dramatic Gains (TheStreet.com)
Jun-20-23 07:04PM	Why Shares of Vera Therapeutics Jumped Tuesday (Motley Fool) +16.94%
09:33AM	2 Surging Healthcare Stocks With More Fuel in the Tank (Motley Fool)
Jun-17-23 10:10AM	Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress (GlobeNewswire)
Jun-15-23 04:44PM	Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN (GlobeNewswire)
Jun-12-23 12:05PM	Why Shares of Vera Therapeutics Are Soaring Monday (Motley Fool) +15.83%
Jun-11-23 01:08PM	7 Stocks That Wall Street Analysts Are Loving in June (InvestorPlace)
Jun-08-23 08:00AM	Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
Jun-07-23 08:00AM	Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN) (GlobeNewswire)
May-11-23 08:36AM	Should You Buy Vera Therapeutics (VERA) Ahead of Earnings? (Zacks)
07:30AM	Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results (GlobeNewswire)
May-04-23 08:00AM	Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs (GlobeNewswire)
Mar-28-23 07:30AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fordyce Marshall	PRESIDENT AND CEO	Feb 21 '25	Sale	27.89	10,613	296,032	213,740	Feb 27 04:05 PM
Fordyce Marshall	PRESIDENT AND CEO	Feb 26 '25	Sale	27.65	9,075	250,882	204,665	Feb 27 04:05 PM
MARSHALL FORDYCE	Director	Feb 26 '25	Proposed Sale	27.10	9,075	245,932		Feb 26 04:21 PM
Fordyce Marshall	PRESIDENT AND CEO	Jan 08 '25	Option Exercise	2.90	17,500	50,694	153,578	Jan 10 04:06 PM
Fordyce Marshall	PRESIDENT AND CEO	Jan 08 '25	Sale	41.74	17,500	730,535	143,603	Jan 10 04:06 PM
MARSHALL FORDYCE	Director	Jan 08 '25	Proposed Sale	42.10	17,500	736,750		Jan 08 04:22 PM
Fordyce Marshall	PRESIDENT AND CEO	Dec 19 '24	Option Exercise	2.90	57,661	167,032	143,603	Dec 20 04:06 PM
Fordyce Marshall	PRESIDENT AND CEO	Dec 18 '24	Option Exercise	2.90	17,500	50,694	90,965	Dec 20 04:06 PM
Fordyce Marshall	PRESIDENT AND CEO	Dec 18 '24	Sale	43.07	17,500	753,680	85,942	Dec 20 04:06 PM
MARSHALL FORDYCE	Director	Dec 18 '24	Proposed Sale	43.91	17,500	768,425		Dec 18 04:24 PM
Fordyce Marshall	PRESIDENT AND CEO	Dec 11 '24	Option Exercise	2.90	17,500	50,694	100,867	Dec 13 04:07 PM
Fordyce Marshall	PRESIDENT AND CEO	Dec 11 '24	Sale	46.94	17,500	821,523	85,942	Dec 13 04:07 PM
MARSHALL FORDYCE	Director	Dec 11 '24	Proposed Sale	46.92	17,500	821,100		Dec 11 04:59 PM
Fordyce Marshall	PRESIDENT AND CEO	Nov 25 '24	Option Exercise	2.90	19,375	56,125	93,607	Nov 27 04:05 PM
Fordyce Marshall	PRESIDENT AND CEO	Nov 25 '24	Sale	47.98	19,375	929,560	85,942	Nov 27 04:05 PM
MARSHALL FORDYCE	Director	Nov 25 '24	Proposed Sale	48.31	19,375	936,006		Nov 25 04:40 PM
Fordyce Marshall	PRESIDENT AND CEO	Nov 13 '24	Option Exercise	2.90	30,625	88,714	98,160	Nov 15 04:05 PM
Fordyce Marshall	PRESIDENT AND CEO	Nov 13 '24	Sale	49.50	30,625	1,516,037	85,942	Nov 15 04:05 PM
MARSHALL FORDYCE	Director	Nov 13 '24	Proposed Sale	48.54	30,625	1,486,538		Nov 13 04:23 PM
SEIDENBERG BETH C	Director	Oct 28 '24	Sale	48.03	15,000	720,493	131,553	Oct 30 04:06 PM
BETH C SEIDENBERG	Director	Oct 28 '24	Proposed Sale	41.09	15,000	616,350		Oct 28 04:37 PM
Fordyce Marshall	PRESIDENT AND CEO	Oct 23 '24	Option Exercise	2.90	19,375	56,126	320,687	Oct 25 04:04 PM
Fordyce Marshall	PRESIDENT AND CEO	Oct 23 '24	Sale	40.39	19,375	782,610	307,972	Oct 25 04:04 PM
MARSHALL FORDYCE	Director	Oct 23 '24	Proposed Sale	40.71	19,375	788,756		Oct 23 04:16 PM
Fordyce Marshall	PRESIDENT AND CEO	Oct 09 '24	Option Exercise	2.90	15,625	45,262	320,245	Oct 11 04:05 PM
Fordyce Marshall	PRESIDENT AND CEO	Oct 09 '24	Sale	38.24	15,625	597,568	307,972	Oct 11 04:05 PM
MARSHALL FORDYCE	Director	Oct 09 '24	Proposed Sale	38.64	15,625	603,750		Oct 09 04:17 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 25 '24	Option Exercise	2.90	23,125	66,988	316,615	Sep 27 04:05 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 25 '24	Sale	46.05	23,125	1,064,809	307,972	Sep 27 04:05 PM
MARSHALL FORDYCE	Director	Sep 25 '24	Proposed Sale	46.71	7,500	350,325		Sep 25 04:21 PM
SEIDENBERG BETH C	Director	Sep 19 '24	Sale	42.31	13,823	584,793	146,553	Sep 20 04:45 PM
SEIDENBERG BETH C	Director	Sep 18 '24	Sale	42.00	1,476	61,992	4,012	Sep 20 04:45 PM
SEIDENBERG BETH C	Director	Sep 18 '24	Sale	42.01	1,177	49,448	160,376	Sep 20 04:45 PM
BETH C SEIDENBERG	Director	Sep 18 '24	Proposed Sale	40.02	15,000	600,300		Sep 18 04:38 PM
SAMUEL B SEIDENBERG IRREV TRUS	Director	Sep 18 '24	Proposed Sale	40.02	1,476	59,070		Sep 18 04:38 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 11 '24	Option Exercise	2.90	15,625	45,262	317,246	Sep 13 04:36 PM
Fordyce Marshall	PRESIDENT AND CEO	Sep 11 '24	Sale	37.50	15,625	585,934	307,972	Sep 13 04:36 PM
MARSHALL FORDYCE	Director	Sep 11 '24	Proposed Sale	37.55	31,250	1,173,438		Sep 11 04:19 PM
Fordyce Marshall	PRESIDENT AND CEO	Aug 28 '24	Option Exercise	2.90	15,625	45,262	337,592	Aug 30 04:04 PM
Fordyce Marshall	PRESIDENT AND CEO	Aug 28 '24	Sale	36.84	30,320	1,117,140	307,972	Aug 30 04:04 PM
MARSHALL FORDYCE	Director	Aug 28 '24	Proposed Sale	37.65	30,320	1,141,548		Aug 28 04:15 PM
Fordyce Marshall	PRESIDENT AND CEO	Aug 21 '24	Sale	39.76	14,471	575,425	322,667	Aug 23 05:40 PM
Fordyce Marshall	PRESIDENT AND CEO	Aug 14 '24	Option Exercise	2.90	15,625	45,262	352,763	Aug 16 04:31 PM
Fordyce Marshall	PRESIDENT AND CEO	Aug 14 '24	Sale	37.56	15,625	586,927	337,138	Aug 16 04:31 PM
MARSHALL FORDYCE	Director	Aug 14 '24	Proposed Sale	37.95	15,625	592,969		Aug 14 04:24 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	May 16 '24	Option Exercise	7.87	20,651	162,523	69,357	May 17 04:21 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	May 15 '24	Option Exercise	3.94	8,221	32,387	61,392	May 17 04:21 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	May 16 '24	Sale	42.32	20,651	873,890	51,206	May 17 04:21 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	May 15 '24	Sale	42.27	10,186	430,546	51,206	May 17 04:21 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Apr 10 '24	Sale	40.00	5,714	228,560	53,171	Apr 12 04:02 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Apr 03 '24	Option Exercise	14.87	99,828	1,484,442	166,165	Apr 05 09:32 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Apr 03 '24	Sale	39.61	99,828	3,954,516	66,337	Apr 05 09:32 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Apr 03 '24	Sale	39.42	18,649	735,205	0	Apr 05 09:32 PM
Katabi Maha	Director	Mar 22 '24	Sale	40.51	413,450	16,748,860	3,133,987	Mar 25 09:46 PM
Katabi Maha	Director	Mar 25 '24	Sale	40.50	340,000	13,770,000	2,793,987	Mar 25 09:46 PM
Katabi Maha	Director	Mar 21 '24	Sale	44.20	81,009	3,580,723	3,547,437	Mar 25 09:46 PM

Dollar change +0.07
Percentage change 2.57	%

VTGN Vistagen Therapeutics Inc daily Stock Chart

Peers: BIIB NBIX ALNY ONC ACAD CORT EDIT FATE AUPH MDGL

| Held by: VTI VXF PSIL IWC AVSC DFAT

Index	-	P/E	-	EPS (ttm)	-1.58	Insider Own	9.88%	Shs Outstand	28.32M	Perf Week	3.33%
Market Cap	80.53M	Forward P/E	-	EPS next Y	-1.67	Insider Trans	0.00%	Shs Float	26.01M	Perf Month	1.09%
Income	-47.30M	PEG	-	EPS next Q	-0.50	Inst Own	44.86%	Short Float	2.50%	Perf Quarter	7.31%
Sales	0.70M	P/S	115.04	EPS this Y	-14.25%	Inst Trans	3.82%	Short Ratio	2.61	Perf Half Y	-14.15%
Book/sh	2.86	P/B	0.97	EPS next Y	3.65%	ROA	-42.35%	Short Interest	0.65M	Perf Year	-33.73%
Cash/sh	3.07	P/C	0.91	EPS next 5Y	-6.96%	ROE	-46.28%	52W Range	2.22 - 5.74	Perf YTD	-5.42%
Dividend Est.	-	P/FCF	-	EPS past 5Y	43.79%	ROI	-57.53%	52W High	-51.39%	Beta	0.51
Dividend TTM	-	Quick Ratio	9.35	Sales past 5Y	89.88%	Gross Margin	11.86%	52W Low	25.68%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	9.35	EPS Y/Y TTM	54.91%	Oper. Margin	-7566.52%	RSI (14)	51.86	Volatility	6.45% 7.36%
Employees	39	Debt/Eq	0.02	Sales Y/Y TTM	-33.00%	Profit Margin	-6774.22%	Recom	1.00	Target Price	13.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-112.31%	Payout	-	Rel Volume	0.18	Prev Close	2.72
Sales Surprise	-24.15%	EPS Surprise	9.75%	Sales Q/Q	-43.12%	Earnings	Feb 13 AMC	Avg Volume	249.34K	Price	2.79
SMA20	1.88%	SMA50	-2.36%	SMA200	-10.66%	Trades		Volume	44,822	Change	2.57%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-07-23	Upgrade	Jefferies	Hold → Buy	$15
Aug-07-23	Upgrade	Maxim Group	Hold → Buy	$30
Jul-22-22	Downgrade	William Blair	Outperform → Mkt Perform
Jul-22-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-22-22	Downgrade	Jefferies	Buy → Hold
May-20-21	Initiated	Robert W. Baird	Outperform	$9
Feb-18-21	Initiated	Jefferies	Buy	$6
Jan-04-21	Upgrade	William Blair	Mkt Perform → Outperform
Jun-27-18	Initiated	Maxim Group	Buy	$6
Feb-08-18	Reiterated	Chardan Capital Markets	Buy	$30 → $22
Mar-28-17	Initiated	Maxim Group	Buy	$4

Show Previous Ratings

Mar-04-25 08:30AM	Vistagen to Participate in Stifel 2025 Virtual CNS Forum (Business Wire) +6.43%
Feb-20-25 08:30AM	Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference (Business Wire)
Feb-14-25 02:22AM	Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ... (GuruFocus.com)
Feb-13-25 05:55PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:30PM	Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update (Business Wire)
07:51AM	Loading…
Feb-12-25 07:51AM	Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2025 Result (GuruFocus.com)
Feb-06-25 08:30AM	Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025 (Business Wire)
Feb-05-25 08:30AM	Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain (Business Wire)
Jan-15-25 05:16AM	Vistagen reports positive outcomes from Phase IIA cancer cachexia trial (Clinical Trials Arena)
Jan-14-25 08:30AM	Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia (Business Wire)
Jan-10-25 08:30AM	Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder (Business Wire)
Nov-14-24 08:30AM	Vistagen to Present at the Stifel 2024 Healthcare Conference (Business Wire)
Nov-08-24 02:31AM	Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... (GuruFocus.com)
Nov-07-24 07:30PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:20PM	Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update (Business Wire)
07:51AM	Loading…
Nov-06-24 07:51AM	Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Nov-05-24 08:30AM	Vistagen to Present at the 2024 Neuroscience Education Institute Congress (Business Wire)
Nov-01-24 08:30AM	Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 (Business Wire)
Oct-11-24 12:00PM	VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know (Zacks)
Oct-09-24 06:20PM	Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges (GuruFocus.com)
08:30AM	Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day (Business Wire)
Sep-24-24 04:52AM	Vistagen enrols first subject in Phase III trial of social anxiety disorder drug (Clinical Trials Arena)
Sep-23-24 08:30AM	Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder (Business Wire)
Sep-06-24 12:00PM	All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy (Zacks)
Aug-13-24 05:30PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:21PM	Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update (Business Wire)
Aug-06-24 08:30AM	Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024 (Business Wire)
Jul-26-24 06:20AM	3 Stocks Under $15 That Could Make You a Millionaire (InvestorPlace)
Jul-10-24 06:33AM	Vistagen secures new patents for PH80 migraine treatment (Pharmaceutical Technology)
Jul-09-24 08:30AM	Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine (Business Wire) +5.90%
08:30AM	Loading…
Jun-27-24 08:30AM	Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year (Business Wire) +7.08%
Jun-12-24 08:52AM	VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace)
08:02AM	VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2024 Earnings Call Transcript (Insider Monkey)
Jun-11-24 04:20PM	Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update (Business Wire)
Jun-07-24 08:30AM	Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 (Business Wire)
May-29-24 08:30AM	Vistagen to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-23-24 08:30AM	Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference (Business Wire)
May-14-24 06:59AM	3 Must-Have Penny Stocks to Boost Your 2024 Portfolio (InvestorPlace)
May-13-24 10:00AM	Meme Stock Rebound: 3 Reddit Favorites Primed for a Resurgence (InvestorPlace)
May-07-24 08:30AM	Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference (Business Wire)
Apr-25-24 08:30AM	Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue (Business Wire)
Apr-19-24 07:13AM	7 Stocks Under $15 Predicted to Boom in the Next 2 Years (InvestorPlace)
Apr-09-24 01:28PM	Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027 (InvestorPlace)
08:30AM	Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference (Business Wire)
Apr-01-24 08:30AM	Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 (Business Wire)
Mar-31-24 10:00AM	Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027 (InvestorPlace)
Mar-26-24 06:24AM	30 Countries with the Lowest Depression Rates (Insider Monkey)
Mar-11-24 08:30AM	Vistagen to Present at Stifel 2024 Virtual CNS Days (Business Wire)
Feb-28-24 08:30AM	Vistagen to Present at TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-21-24 09:55AM	Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect? (Zacks)
Feb-19-24 12:24PM	3 Revolutionary Biotech Stocks Poised for 10X Surge (InvestorPlace)
Feb-15-24 08:20AM	VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript (Insider Monkey)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +10.00%
Feb-13-24 04:59PM	Vistagen Therapeutics Inc (VTGN) Reports Fiscal 2024 Q3 Results: A Closer Look at Financials ... (GuruFocus.com)
04:20PM	Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update (Business Wire)
Feb-07-24 07:38AM	3 Penny Stocks to Buy for the Next Bull Run: February 2024 (InvestorPlace)
Feb-06-24 08:30AM	Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024 (Business Wire)
Jan-26-24 09:04AM	3 Penny Stocks to Turn $999 Into $1 Million: January 2024 (InvestorPlace)
Dec-29-23 08:40AM	How Vistagen (VTGN) Stock Stands Out in a Strong Industry (Zacks)
Dec-27-23 08:30AM	Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain (Business Wire)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey) -6.85%
Nov-11-23 01:03PM	VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:30PM	Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results (Business Wire) -6.17% -11.07%
Nov-08-23 08:30AM	Vistagen to Present at Stifel 2023 Healthcare Conference (Business Wire) -11.37%
Nov-07-23 08:30AM	Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences (Business Wire)
Nov-06-23 08:00AM	Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023 (Business Wire)
Oct-05-23 08:30AM	Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit (Business Wire) -9.18%
Oct-02-23 07:30AM	Vistagen Announces Pricing of $100 Million Underwritten Offering (Business Wire) -19.85%
Sep-21-23 04:43PM	The 7 Best Short-Squeeze Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-12-23 08:30AM	Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder (Business Wire)
Sep-05-23 09:00AM	Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagens Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan (Business Wire)
Aug-22-23 08:30AM	Vistagen Appoints Cindy Anderson as Chief Financial Officer (Business Wire) +7.68%
Aug-15-23 07:37AM	VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript (Insider Monkey) -9.77%
Aug-11-23 10:34AM	Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News (Zacks) -14.57%
Aug-10-23 04:21PM	Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results (Business Wire) +6.82%
10:31AM	COMMODORE CAPITAL LP Acquires New Stake in Vistagen Therapeutics Inc (GuruFocus.com)
03:49AM	AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder (PR Newswire)
Aug-08-23 04:30PM	Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023 (Business Wire) -43.14% -5.19%
Aug-07-23 05:46PM	Social anxiety nasal spray study results make Peninsula biotech's stock shoot up more than 600% (American City Business Journals) +676.79%
04:12PM	Biotech Firm Pops 677% on Social Anxiety Spray Trial Success (Bloomberg)
08:30AM	Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder (Business Wire)
Jul-17-23 08:00AM	Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Sprays Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain (Business Wire)
Jul-13-23 04:05PM	Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinsons Disease (Business Wire)
Jun-28-23 04:25PM	Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results (Business Wire)
Jun-27-23 04:30PM	Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023 (Business Wire)
Jun-23-23 08:30AM	Vistagen Regains Full Compliance with Nasdaq Listing Requirements (Business Wire)
Jun-21-23 08:30AM	Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder (Business Wire) -7.22%
Jun-16-23 12:36PM	Revolutionizing mental health treatment: Vistagen Therapeutics' nasal spray solution (News Direct)
08:30AM	Vistagen to Participate in the Maxim Group Healthcare Virtual Conference Hosted by M-Vest (Business Wire)
Jun-13-23 08:00AM	Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine (Business Wire) -10.91%
Jun-07-23 09:00AM	Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes (Business Wire) -9.21%
Jun-06-23 04:30PM	Vistagen to Present at Jefferies 2023 Global Healthcare Conference (Business Wire) -25.75%
09:25AM	Vistagen Announces Stockholder-Approved Reverse Stock Split (Business Wire)
Jun-01-23 08:30AM	Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting (Business Wire)
May-30-23 04:15PM	Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting (Business Wire) +6.12%
May-24-23 08:30AM	Vistagen Awarded Mental Health Americas Platinum Bell Seal for Workplace Mental Health (Business Wire)
Apr-19-23 08:30AM	Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference (Business Wire)
Apr-06-23 08:30AM	Vistagen Receives New European Patent for AV-101 (Business Wire)
Mar-30-23 03:18PM	Social Anxiety Disorder Impacts Around 23.7M People In US, Vistagen Releases Details Around Nasal Spray Treatment Program For It (Benzinga)
08:30AM	FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder (Business Wire)

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

VERA

Vera Therapeutics Inc

VTGN

Vistagen Therapeutics Inc

Upgrade your FINVIZ experience